Xeomin is the newest “frown fixer” available to patients across the country. This new neuromodulator acts like its predecessors Botox and Dysport in reducing or preventing contractions of the Glabellar muscle between the eyes. The difference in Xeomin (incobotulinumtoxinA) is that it does not carry the proteins that are typical of the other products. The potential advantage lies in the lessened likelihood of antibodies being formed to the proteins, which – for a very limited number of patients – can render the product ineffective. (This typically is only seen in patients who have used botulinum toxin for an extended period of time.)
The muscle-restricting action is, for all practical purposes, like Botox and Dysport and the dosing will be the same as Botox. So if you’re accustomed to 20 units of Botox, expect to receive 20 units of Xeomin for the same effect and area. Similar to Botox, Xeomin takes effect within 2-3 days after injection with effectiveness ranging up to 4 months.